KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.60

Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.

Katelyn Purvis, Yinmei Zhou, Seth E Karol, Jeffrey E Rubnitz, Raul C Ribeiro, Shawn Lee, Jun J Yang, W Paul Bowman, Lu Wang, Stephanie B Dixon, Kathryn G Roberts, Qingsong Gao, Cheng Cheng, Charles G Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Blood 145(2) 190-201

PMID39316653
PMCIDPMC11738036
DOI10.1182/blood.2024024936
发表日期2024-09-24
入排依据:The record is a secondary analysis of two Phase III RCTs with a time-to-event endpoint (EFS). However, the abstract does not establish a drug-containing intervention; it focuses on risk stratification and outcomes of therapy protocols. Without explicit drug vs. non-drug (or standard-of-care) randomized comparison, the drug_intervention criterion cannot be met.
摘要

摘要

Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years) with these genotypes in the SJ Total XV/XVI studies (2000-2017). Patients with ETV6::RUNX1 (n = 222) or high-hyperdiploid (n = 296) B-ALL had 5-year event-free survival (EFS) of 97.7% ± 1.1% and 94.7% ± 1.4%, respectively. For ETV6::RUNX1, EFS was comparable between NCI standard-risk and high-risk patients and between SJ low-risk and standard-risk patients. Of the 40 NCI high-risk patients, 37 who received SJ low-risk therapy had excellent EFS (97.3% ± 2.8%). For high-hyperdiploid B-ALL, NCI high-risk patients had worse EFS than standard-risk patients (87.6% ± 4.5% vs 96.4% ± 1.3%; P = .016). EFS was similar for NCI standard-risk and high-risk patients classified as SJ low risk (96.0% ± 1.5% and 96.9% ± 3.2%; P = .719). However, EFS was worse for NCI high-risk patients than for NCI standard-risk patients receiving SJ standard/high-risk therapy (77.4% ± 8.2% vs 98.0% ± 2.2%; P = .004). NCI high-risk patients with ETV6::RUNX1 or high-hyperdiploid B-ALL who received SJ low-risk therapy had lower incidences of thrombosis (P = .013) and pancreatitis (P = .011) than those who received SJ standard/high-risk therapy. MRD-directed therapy yielded excellent outcomes, except for NCI high-risk high-hyperdiploid B-ALL patients with slow MRD response, who require new treatment approaches. Among NCI high-risk patients, 93% with ETV6::RUNX1 and 54% with high-hyperdiploid B-ALL experienced excellent outcomes with a low-intensity regimen. These trials were registered at www.clinicaltrials.gov as #NCT00137111 and #NCT00549848.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。